CN119792555A - 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 - Google Patents
用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 Download PDFInfo
- Publication number
- CN119792555A CN119792555A CN202510138513.7A CN202510138513A CN119792555A CN 119792555 A CN119792555 A CN 119792555A CN 202510138513 A CN202510138513 A CN 202510138513A CN 119792555 A CN119792555 A CN 119792555A
- Authority
- CN
- China
- Prior art keywords
- paclitaxel
- treatment
- pharmaceutical composition
- prodrug
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009731 | 2018-10-25 | ||
| IT102018000009731A IT201800009731A1 (it) | 2018-10-25 | 2018-10-25 | Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante |
| CN201980064603.9A CN112805035A (zh) | 2018-10-25 | 2019-10-23 | 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 |
| PCT/IB2019/059073 WO2020084525A1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980064603.9A Division CN112805035A (zh) | 2018-10-25 | 2019-10-23 | 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119792555A true CN119792555A (zh) | 2025-04-11 |
Family
ID=65324453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510138513.7A Pending CN119792555A (zh) | 2018-10-25 | 2019-10-23 | 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 |
| CN201980064603.9A Pending CN112805035A (zh) | 2018-10-25 | 2019-10-23 | 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980064603.9A Pending CN112805035A (zh) | 2018-10-25 | 2019-10-23 | 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20200397909A1 (enExample) |
| EP (1) | EP3870233B1 (enExample) |
| JP (1) | JP7518815B2 (enExample) |
| KR (1) | KR102913965B1 (enExample) |
| CN (2) | CN119792555A (enExample) |
| CA (1) | CA3112188A1 (enExample) |
| DK (1) | DK3870233T3 (enExample) |
| EA (1) | EA202190614A1 (enExample) |
| ES (1) | ES2971217T3 (enExample) |
| FI (1) | FI3870233T3 (enExample) |
| HR (1) | HRP20240188T1 (enExample) |
| HU (1) | HUE066288T2 (enExample) |
| IT (1) | IT201800009731A1 (enExample) |
| LT (1) | LT3870233T (enExample) |
| MA (1) | MA63879B1 (enExample) |
| PL (1) | PL3870233T3 (enExample) |
| PT (1) | PT3870233T (enExample) |
| RS (1) | RS65193B1 (enExample) |
| SI (1) | SI3870233T1 (enExample) |
| SM (1) | SMT202400021T1 (enExample) |
| WO (1) | WO2020084525A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000007747A1 (it) * | 2020-04-10 | 2021-10-10 | Fidia Farm Spa | Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma |
| IT202000008209A1 (it) * | 2020-04-17 | 2021-10-17 | Fidia Farm Spa | Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2553099B1 (fr) | 1983-10-11 | 1989-09-08 | Fidia Spa | Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant |
| IT1263393B (it) | 1993-07-30 | 1996-08-05 | Fidia Advanced Biopolymers Srl | Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare |
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| ITPD20020271A1 (it) * | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| AR047938A1 (es) * | 2003-08-25 | 2006-03-15 | Combinatorx Inc | Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas |
| ITMI20071267A1 (it) | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
| IT1402384B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium |
| IT1402385B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis |
| ES2653679T3 (es) | 2011-11-09 | 2018-02-08 | Spinalcyte, Llc | Fibroblastos dérmicos para el tratamiento de enfermedad discal degenerativa |
| IT201600079633A1 (it) | 2016-07-28 | 2018-01-28 | Fidia Farm Spa | Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico |
| CN110859962B (zh) | 2019-11-25 | 2021-01-22 | 山东大学 | 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用 |
-
2018
- 2018-10-25 IT IT102018000009731A patent/IT201800009731A1/it unknown
-
2019
- 2019-10-23 LT LTEPPCT/IB2019/059073T patent/LT3870233T/lt unknown
- 2019-10-23 SI SI201831054T patent/SI3870233T1/sl unknown
- 2019-10-23 CN CN202510138513.7A patent/CN119792555A/zh active Pending
- 2019-10-23 HU HUE19801630A patent/HUE066288T2/hu unknown
- 2019-10-23 JP JP2021515655A patent/JP7518815B2/ja active Active
- 2019-10-23 MA MA63879A patent/MA63879B1/fr unknown
- 2019-10-23 RS RS20240122A patent/RS65193B1/sr unknown
- 2019-10-23 DK DK19801630.5T patent/DK3870233T3/da active
- 2019-10-23 SM SM20240021T patent/SMT202400021T1/it unknown
- 2019-10-23 PL PL19801630.5T patent/PL3870233T3/pl unknown
- 2019-10-23 FI FIEP19801630.5T patent/FI3870233T3/fi active
- 2019-10-23 ES ES19801630T patent/ES2971217T3/es active Active
- 2019-10-23 PT PT198016305T patent/PT3870233T/pt unknown
- 2019-10-23 KR KR1020217007729A patent/KR102913965B1/ko active Active
- 2019-10-23 EP EP19801630.5A patent/EP3870233B1/en active Active
- 2019-10-23 US US16/959,979 patent/US20200397909A1/en not_active Abandoned
- 2019-10-23 EA EA202190614A patent/EA202190614A1/ru unknown
- 2019-10-23 HR HRP20240188TT patent/HRP20240188T1/hr unknown
- 2019-10-23 CA CA3112188A patent/CA3112188A1/en active Pending
- 2019-10-23 WO PCT/IB2019/059073 patent/WO2020084525A1/en not_active Ceased
- 2019-10-23 CN CN201980064603.9A patent/CN112805035A/zh active Pending
-
2021
- 2021-03-17 US US17/204,183 patent/US20210196833A1/en not_active Abandoned
- 2021-05-10 US US17/315,962 patent/US12465649B2/en active Active
-
2023
- 2023-12-14 US US18/539,827 patent/US20240123077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2971217T3 (es) | 2024-06-04 |
| KR102913965B1 (ko) | 2026-01-16 |
| IT201800009731A1 (it) | 2020-04-25 |
| JP2022503771A (ja) | 2022-01-12 |
| EP3870233B1 (en) | 2023-12-06 |
| FI3870233T3 (fi) | 2024-02-07 |
| LT3870233T (lt) | 2024-02-26 |
| SMT202400021T1 (it) | 2024-03-13 |
| PT3870233T (pt) | 2024-02-01 |
| DK3870233T3 (da) | 2024-02-05 |
| JP7518815B2 (ja) | 2024-07-18 |
| US20240123077A1 (en) | 2024-04-18 |
| EA202190614A1 (ru) | 2021-06-03 |
| PL3870233T3 (pl) | 2024-05-06 |
| CA3112188A1 (en) | 2020-04-30 |
| US20210268119A1 (en) | 2021-09-02 |
| KR20210083249A (ko) | 2021-07-06 |
| US12465649B2 (en) | 2025-11-11 |
| EP3870233A1 (en) | 2021-09-01 |
| HRP20240188T1 (hr) | 2024-05-10 |
| CN112805035A (zh) | 2021-05-14 |
| HUE066288T2 (hu) | 2024-07-28 |
| RS65193B1 (sr) | 2024-03-29 |
| WO2020084525A1 (en) | 2020-04-30 |
| SI3870233T1 (sl) | 2024-03-29 |
| MA63879B1 (fr) | 2024-02-29 |
| US20200397909A1 (en) | 2020-12-24 |
| US20210196833A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martin et al. | Glycosidase activated prodrugs for targeted cancer therapy | |
| Wang et al. | Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies | |
| Fiorica et al. | A hyaluronic acid/cyclodextrin based injectable hydrogel for local doxorubicin delivery to solid tumors | |
| ES2544481T3 (es) | Taxanos unidos covalentemente a ácido hialurónico | |
| CN101965201B (zh) | 淋巴管内化疗药物载体 | |
| JP2005517048A (ja) | シクロデキストリングラフト生体適合性両親媒性ポリマーおよびその製造および使用方法 | |
| US20240123077A1 (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| WO2019210414A1 (en) | Fucan-based compounds and complexes | |
| US10478132B2 (en) | Glucose conjugated gold nanoparticle | |
| JP5982361B2 (ja) | 組織標的化方法 | |
| CN115667214A (zh) | 包括药物二聚体的纳米颗粒及其用途 | |
| Yu et al. | Superior antitumor effect of self-assembly supramolecular paclitaxel nanoparticles | |
| Liang et al. | Acid-degradable magnolol-containing polymeric prodrug micelles for enhanced gastric cancer therapy | |
| EA043782B1 (ru) | Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря | |
| HK40048954A (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| HK40048954B (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| JPWO2005037292A1 (ja) | 糖鎖含有キトサン誘導体を含有する内視鏡手術用粘膜下膨隆液組成物 | |
| CN121891549A (zh) | 一种基于紫杉醇衍生物的组合物及其制备方法和应用 | |
| Alvi | Lysosomal targeting of a gelatin-doxorubicin conjugate and its evaluation for cell damage in two model breast cancer cell lines | |
| Supasena | Synthesis and characterization of polyethylene glycol-doxorubicin conjugates containing β-thiopropanamide linkers for enhanced selective cytotoxicity against breast cancer cells | |
| 박주호 | Design and therapeutic evaluation of heparin based bioconjugate for oral delivery and antiangiogenic therapy | |
| US20180251574A1 (en) | Fucan-dendrimer based compounds and complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |